<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581515</url>
  </required_header>
  <id_info>
    <org_study_id>1-2011-0080</org_study_id>
    <nct_id>NCT01581515</nct_id>
  </id_info>
  <brief_title>Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation</brief_title>
  <acronym>ANCHOR</acronym>
  <official_title>2-phased Randomized Comparison Between PromusTMElementTM Versus Xience PRIME® Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the degree of stent malapposition on an immediate
      optical coherence tomography (OCT) after nominal stent pressure and at a final post-procedure
      OCT (ANCHOR-I) and the neointimal coverage on 3-months OCT following the intervention with
      the randomly assigned two drug-eluting stents (DES), PromusTMElementTM stents versus Xience
      PRIME® stents.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the ratio of the malapposed strut</measure>
    <time_frame>Participants will be followed from first OCT invervention to 3month OCT following intervention</time_frame>
    <description>The ratio of the malapposed strut, on an immediate OCT after nominal stent pressure and at a final post-procedure between two different DES; ANCHOR-I</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of stent malapposition</measure>
    <time_frame>3months OCT following intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neointimal coverage(ANCHOR II)</measure>
    <time_frame>3 month-OCT after stent implantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of plaque prolapse</measure>
    <time_frame>final postprocedural OCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of stent expansion</measure>
    <time_frame>an immediate and post-procedural OCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent malapposition</measure>
    <time_frame>on 3 month OCT intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>P-E group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>X-P group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Promus Element everolimus eluting coronary stent</intervention_name>
    <description>Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime</description>
    <arm_group_label>P-E group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xience Prime everolimus eluting coronary stent</intervention_name>
    <description>Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime</description>
    <arm_group_label>X-P group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ≥ 20 years old

          -  Significant coronary de novo lesion (&gt; 70% by quantitative angiographic analysis)
             treated by single DES in each vessel.

          -  Patients with stable angina who are considered for coronary revascularization with
             stent implantation.

          -  Reference vessel diameter of 2.5 to 3.5 mm by operator assessment

        Exclusion Criteria:

          -  Complex lesion morphologies such as aorto-ostial, unprotected left main, chronic total
             occlusion, graft, thrombosis, and restenosis

          -  Reference vessel diameter &lt; 2.5 mm or &gt; 4.0mm and lesion length &gt; 28 mm

          -  Heavy calcified lesions (definite calcified lesions on angiogram)

          -  Lesions requiring more than 2 DES in each vessel

          -  Acute coronary syndrome

          -  Contraindication to anti-platelet agents

          -  Treated with any DES within 3 months at other vessel

          -  Creatinine level ≥ 2.0 mg/dL or ESRD

          -  Severe hepatic dysfunction (3 times normal reference values)

          -  Pregnant women or women with potential childbearing

          -  Life expectancy 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myeong-Ki Hong, MD.PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myeong-Ki Hong, MD.PhD.</last_name>
    <phone>+82 2 2228 8458</phone>
    <email>mkhong61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu/Sinchon-dong</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin-young Park, Staff</last_name>
      <phone>+82 2 2228 0453</phone>
      <email>smile@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Myeong-Ki Hong, MD.PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>April 17, 2012</last_update_submitted>
  <last_update_submitted_qc>April 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Myeong-Ki Hong</investigator_full_name>
    <investigator_title>MD, Ph D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

